after Shanghai Sunway Biotech's Oncorine for nasopharyngeal carcinoma in 2005 and Amgen's Imlygic (talimogene laherparepvec) for melanoma 10 years later. While still a niche area of immuno ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.